. Author manuscript; available in PMC: 2019 May 15.

Published in final edited form as: Bioorg Med Chem. 2018 Feb 2;26(9):2251–2261. doi: 10.1016/j.bmc.2018.01.024

Table 6.

Activity of 41F5-derived antifungals against fluconazole-resistant Cryptococcus isolates

Cmpd	H99 (serotype A-Flu^S)		B3501 (serotype D-Flu^S)		TES9^a (serotype A-Flu^R)		MRL862^a (serotype A-Flu^R)

	IC₅₀ (µM) [±SD]^b	MIC (µM)	IC₅₀ (µM) [±SD]	MIC (µM)	IC₅₀ (µM) [±SD]	MIC (µM)	IC₅₀ (µM) [±SD]	MIC (µM)
41F5	0.67 [±0.06]	1.25	0.18 [±0.17]	0.63	0.20 [±0.03]	0.63	0.23 [±0.04]	0.63
Fluconazole	0.95 [±0.63]	4.08	0.13 [±0.22]	2.04	27.38 [±2.17]	65.36	14.61 [±0.65]	32.68
17b	0.34 [±0.04]	0.63	0.27 [±0.02]	0.63	0.23 [±0.01]	0.63	0.20 [±0.02]	0.63
21b	0.62 [±0.12]	2.50	0.32 [±0.02]	0.63	0.41 [±0.02]	0.63	0.15 [±0.09]	0.63
22b	0.21 [±0.09]	0.63	0.16 [±0.03]	0.63	0.19 [±0.01]	0.31	0.13 [±0.01]	0.31
26b	0.41 [±0.07]	1.25	0.42 [±0.06]	1.25	0.45 [±0.07]	1.25	0.37 [±0.58]	1.25
36b	0.89 [±0.32]	2.50	0.38 [±0.06]	1.25	0.47 [±0.05]	1.25	0.41 [±0.05]	1.25

TES9 and MRL862 are fluconazole-resistant (Flu^R) strains due to mutation of the azole target Erg11.

SD: Standard deviation